Loading...
PDEX logo

Pro-Dex, Inc.NasdaqCM:PDEX Aktierapport

Marknadsvärde US$202.8m
Aktiekurs
US$63.52
US$70
9.3% undervärderad intrinsisk rabatt
1Y44.0%
7D4.5%
1D
Portföljens värde
​
Utsikt

Pro-Dex, Inc.

NasdaqCM:PDEX Aktierapport

Börsvärde: US$202.8m

Pro-Dex (PDEX) Aktievy

Pro-Dex, Inc. designar, utvecklar, tillverkar och säljer motordrivna kirurgiska instrument till originaltillverkare av medicinteknisk utrustning över hela världen. Mer information

PDEX fundamental analys
Snöflinga Score
Värdering2/6
Framtida tillväxt0/6
Tidigare resultat5/6
Finansiell hälsa6/6
Utdelningar0/6

Belöningar

Pris-till-vinst-förhållandet ( 16.9 x) är lägre än US marknaden ( 18.6 x)

Intäkterna ökade med 28.1% under det senaste året

Riskanalys

Intäkterna förväntas minska med i genomsnitt 20.3% per år under de kommande 3 åren

Stora engångsposter som påverkar finansiella resultat


PDEX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Pro-Dex, Inc. Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Pro-Dex
Historiska aktiekurser
Aktuell aktiekursUS$63.52
52 veckors högstaUS$64.69
52 veckors lägstaUS$23.47
Beta-0.11
1 månads förändring21.92%
3 månaders förändring49.11%
1 års förändring44.00%
3 års förändring233.44%
5 års förändring88.82%
Förändring sedan börsintroduktionen1,068.17%

Senaste nyheter och uppdateringar

Recent updates

Analysartikel • Jan 10

We Think Pro-Dex (NASDAQ:PDEX) Can Manage Its Debt With Ease

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysartikel • Nov 14

Even With A 26% Surge, Cautious Investors Are Not Rewarding Pro-Dex, Inc.'s (NASDAQ:PDEX) Performance Completely

Those holding Pro-Dex, Inc. ( NASDAQ:PDEX ) shares would be relieved that the share price has rebounded 26% in the last...
Analysartikel • Sep 09

Earnings Working Against Pro-Dex, Inc.'s (NASDAQ:PDEX) Share Price Following 26% Dive

Pro-Dex, Inc. ( NASDAQ:PDEX ) shares have had a horrible month, losing 26% after a relatively good period beforehand...
Analysartikel • Sep 06

We Think Pro-Dex (NASDAQ:PDEX) Can Stay On Top Of Its Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysartikel • Aug 13

With EPS Growth And More, Pro-Dex (NASDAQ:PDEX) Makes An Interesting Case

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysartikel • May 31

Pro-Dex, Inc.'s (NASDAQ:PDEX) 39% Dip In Price Shows Sentiment Is Matching Earnings

The Pro-Dex, Inc. ( NASDAQ:PDEX ) share price has softened a substantial 39% over the previous 30 days, handing back...
Analysartikel • May 04

Here's Why Pro-Dex (NASDAQ:PDEX) Has Caught The Eye Of Investors

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysartikel • Apr 16

Pro-Dex, Inc.'s (NASDAQ:PDEX) P/E Is Still On The Mark Following 29% Share Price Bounce

Pro-Dex, Inc. ( NASDAQ:PDEX ) shares have continued their recent momentum with a 29% gain in the last month alone. The...
Analysartikel • Apr 03

Pro-Dex (NASDAQ:PDEX) Looks To Prolong Its Impressive Returns

What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Analysartikel • Feb 24

This Analyst Just Made A Decent Upgrade To Their Pro-Dex, Inc. (NASDAQ:PDEX) Earnings Forecasts

Pro-Dex, Inc. ( NASDAQ:PDEX ) shareholders will have a reason to smile today, with the covering analyst making...
Analysartikel • Feb 05

Some Pro-Dex, Inc. (NASDAQ:PDEX) Shareholders Look For Exit As Shares Take 27% Pounding

Pro-Dex, Inc. ( NASDAQ:PDEX ) shares have had a horrible month, losing 27% after a relatively good period beforehand...
Analysartikel • Nov 13

This Analyst Just Made A Massive Upgrade To Their Pro-Dex, Inc. (NASDAQ:PDEX) Earnings Forecasts

Pro-Dex, Inc. ( NASDAQ:PDEX ) shareholders will have a reason to smile today, with the covering analyst making...
Analysartikel • Nov 05

Pro-Dex, Inc. (NASDAQ:PDEX) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected

Despite an already strong run, Pro-Dex, Inc. ( NASDAQ:PDEX ) shares have been powering on, with a gain of 31% in the...
Analysartikel • Sep 10

Pro-Dex, Inc.'s (NASDAQ:PDEX) P/E Is Still On The Mark Following 37% Share Price Bounce

The Pro-Dex, Inc. ( NASDAQ:PDEX ) share price has done very well over the last month, posting an excellent gain of 37...
Analysartikel • Jul 18

The Returns On Capital At Pro-Dex (NASDAQ:PDEX) Don't Inspire Confidence

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...
Analysartikel • Feb 16

Investors Can Find Comfort In Pro-Dex's (NASDAQ:PDEX) Earnings Quality

Pro-Dex, Inc.'s ( NASDAQ:PDEX ) earnings announcement last week didn't impress shareholders. While the headline numbers...
Analysartikel • Feb 14

Here's Why Pro-Dex (NASDAQ:PDEX) Can Manage Its Debt Responsibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysartikel • Jan 24

Pro-Dex, Inc.'s (NASDAQ:PDEX) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Pro-Dex, Inc. ( NASDAQ:PDEX ) shareholders have had their patience rewarded with a 26% share price jump in the last...
Analysartikel • May 20

Pro-Dex (NASDAQ:PDEX) Has A Pretty Healthy Balance Sheet

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysartikel • Oct 05

Pro-Dex (NASDAQ:PDEX) Could Be Struggling To Allocate Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Seeking Alpha • Sep 26

Pro-Dex: Growth Trends In Earnings, Return On Investment Contracting

Summary Following its FY22 numbers Pro-Dex continues to realize a softening set of fundamentals. Growth trends in earnings and return on investment have been contracting on a sequential basis throughout the pandemic. Valuations do not support substantial upside, in my estimation. Net-net I've rated PDEX a hold with a $14.30 price target which reflects 10.5x FY23 earnings estimates. Investment summary The market has been doing all of the talking in in FY22 and in doing so has been doing the heavy lifting for us stock pickers. If you consider the market to be somewhat efficient [we do], and are an avid believer in data-driven fundamentals [again], then you'd have to agree that there's been a sigh of relief with the unwinding of the high-beta, growth trade of FY20'–21'. Investors are finally paying attention to fundamentals again, and the resulting factor rotation into defensives, quality and the likes has seen a rapid drawdown in wildly valued companies. Whilst we can think tech and private equity all we want, of equal substance here is the health care and medical technology ("medtech") sector[s]. Of no fault of its own, the medical and surgical equipment domains caught a strong bid across FY21 even with weakening fundamentals across the time period. Case in point is Pro-Dex, Inc (PDEX) whereby investors rewarded narrative versus numbers during the pandemic. The stock trades around 52-week lows and continues to push lower as the market continues to deal with the overvalued pockets that still linger around to this day. I've found the company's fundamentals have been weakening over the past 2 years and that investors may have been correct in re-rating the stock to its lowest average market cap in around 2-years. Net-net, I rate PDEX a hold, and note valuations are supportive of this view along with the above-mentioned points. For a quick overview, the company designs and manufactures surgical devices used in the thoracic, orthopaedic and craniomaxillofacial ("CMF") markets. It manufactures multifunctional surgical drivers and shavers that use the company's 'adaptive torque-limiting technology' and other IP that is sells to distributors. It books revenue on this basis and here, I've gone a little deeper into the company's numbers to understand how it is spending its money, and what value it is creating on this. PDEX FY22 results illustrate market headwinds The company came in with a weak set of results in FY22 compared to the previous 12 months. Net sales of $42.04 million ("mm") came in on a 10.5% YoY growth schedule whereas the cost of this turnover increased 18.2% YoY to $28.9mm. This led gross margin to compress by ~440bps YoY to 31.2%. Moving down the P&L, and OPEX came in 11% lower than FY21 due to reduced selling expenditure and a 32% YoY reduction to R&D spend. As such, PDEX recognized some upward mobility in operating income to $5.1mm and brought this down to a net income of $3.855mm, well behind FY21's $5.82mm in net profit. However, I'd note FY21 included $2.47mm in 'other' income that wasn't booked in FY22, and removing this from the equation earnings actually stretched up by 15% YoY. Meanwhile, it printed a loss of $2.52mm in FCF for the year. PDEX's FCF bridge for the 12 months is seen in Exhibit 1. Medical device sales make up 81% of turnover for PDEX, made up of revenue from orthopaedic, CMF and thoracic segments. Orthopaedic sales lifted 21.9% YoY and printed $21.87mm and made up 64% of total medical device turnover. Exhibit 1. Note: All figures in $mm. (Data: HB Insights, PDEX SEC Filings) PDEX fair view of fundamentals Deeper analysis on the company's FY22 numbers illustrate that concentration risk from customer's increased YoY. To illustrate, PDEX's top 3 customers attributed 88% of sales compared to 91% the year prior. However, there was 1 customer that accounted for ~66% of turnover, with the second largest customer generating 14%. Compared to FY21 the breakdown was 58% and 27% respectively. PDEX also had a backlog of $16.5mm at the end of FY22, and this was up 70.1% YoY and management said this is backed by firm purchase orders. Meanwhile, distribution of gross–operating profit has been lumpy on a sequential basis from FY20 to date, as seen in Exhibit 2. Similar trends are observed in free cash flow ("FCF") and FCF yield. Whereas PDEX recognized solid growth numbers from FY16–FY19 on a quarterly basis, this pattern has become less consistent throughout the pandemic, such that operating profit narrowed by CAGR 25.7% over this time. On this, TTM FCF yields have continued their descent from FY17, and PDEX realized a cumulative FCF loss of $10.75mm across the course of the pandemic. Exhibit 2. Reversal of [profit] growth trends from top to bottom line throughout pandemic. FCF yields continued descent – question becomes if there is the return on capital/investment to measure this as a positive result. Cumulative $10.75mm FCF loss across course of pandemic [quarterly]. Note: All figures in $mm or [%]. Free cash flow calculated as [NOPAT - investments]. FCF yield as a function of enterprise value on trailing twelve month basis. All calculations made from GAAP earnings with no reconciliations. (Image: HB Insights. Data: HB Insights, PDEX SEC Filings. ) The question then becomes if the FCF 'spend' has been realized back in the company's return on investment. In particular, I wanted to examine how much NOPAT the company generated from the previous period's invested capital. I've measured this as return on invested capital ("ROIC") and return on assets ("ROA") on a TTM basis. As seen in Exhibit 3, there is no divergence in the PDEX's return on investment to the FCF yield from FY20 to date. Both have been contracting in this time. Ideally, we'd see some bifurcation of ROIC and ROA to the upside, indicating that FCF was well 'spent' over the testing period, however this isn't the case in my estimation. From what we've observed so far in FY22, names that have been growing return on investment over the past 5 years have withstood the downside this YTD. Hence, this is an important factor in the PDEX investment debate. Exhibit 4. Positive correlation of PDEX's return on investment [ROIC, ROA], to FCF yield.
Analysartikel • Sep 20

When Should You Buy Pro-Dex, Inc. (NASDAQ:PDEX)?

While Pro-Dex, Inc. ( NASDAQ:PDEX ) might not be the most widely known stock at the moment, it saw a decent share price...
Seeking Alpha • Aug 25

Pro-Dex GAAP EPS of $0.38, revenue of $12.61M

Pro-Dex press release (NASDAQ:PDEX): Q4 GAAP EPS of $0.38. Revenue of $12.61M (+33.6% Y/Y).
Analysartikel • May 10

Is Now The Time To Look At Buying Pro-Dex, Inc. (NASDAQ:PDEX)?

Pro-Dex, Inc. ( NASDAQ:PDEX ), is not the largest company out there, but it received a lot of attention from a...
Analysartikel • Apr 21

Is Pro-Dex (NASDAQ:PDEX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysartikel • Mar 14

Pro-Dex (NASDAQ:PDEX) Is Doing The Right Things To Multiply Its Share Price

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Analysartikel • Feb 09

Is Pro-Dex, Inc. (NASDAQ:PDEX) Potentially Undervalued?

Pro-Dex, Inc. ( NASDAQ:PDEX ), might not be a large cap stock, but it saw significant share price movement during...
Analysartikel • Nov 17

We Think Pro-Dex (NASDAQ:PDEX) Is Taking Some Risk With Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Aktieägarnas avkastning

PDEXUS Medical EquipmentUS Marknad
7D4.5%1.8%1.2%
1Y44.0%-17.9%28.7%

Avkastning vs industri: PDEX översteg US Medical Equipment branschen som gav -17.9 % under det senaste året.

Avkastning vs Marknaden: PDEX översteg US marknaden som gav 28.7 % under det senaste året.

Prisvolatilitet

Is PDEX's price volatile compared to industry and market?
PDEX volatility
PDEX Average Weekly Movement6.6%
Medical Equipment Industry Average Movement8.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stabil aktiekurs: PDEX har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: PDEX s veckovolatilitet ( 7% ) har varit stabil under det senaste året.

Om företaget

GrundadAnställdaVD OCH KONCERNCHEFWebbplats
1978180Rick Van Kirkwww.pro-dex.com

Pro-Dex, Inc. designar, utvecklar, tillverkar och säljer motordrivna kirurgiska instrument till tillverkare av originalutrustning för medicintekniska produkter över hela världen. Företaget erbjuder autoklaverbara, batteridrivna och elektriska samt multifunktionella kirurgiska drivare och rakapparater som främst används på marknaderna för ortopedi, thorax och kraniomaxillofacial kirurgi. Företaget tillhandahåller även konsulttjänster inom teknik, kvalitet och regelverk samt tillverkar och säljer roterande luftmotorer till olika branscher.

Pro-Dex, Inc. Sammanfattning av grunderna

Hur förhåller sig Pro-Dex:s resultat och omsättning till dess börsvärde?
PDEX grundläggande statistik
BörsvärdeUS$202.80m
Vinst(TTM)US$12.00m
Intäkter(TTM)US$74.64m
16.9x
P/E-förhållande
2.7x
P/S-förhållande

Är PDEX övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
PDEX resultaträkning (TTM)
IntäkterUS$74.64m
Kostnad för intäkterUS$53.90m
BruttovinstUS$20.74m
Övriga kostnaderUS$8.73m
IntäkterUS$12.00m

Senast redovisade vinst

Mar 31, 2026

Nästa vinstdatum

n/a

Vinst per aktie (EPS)3.76
Bruttomarginal27.78%
Nettovinstmarginal16.08%
Skuld/egenkapitalförhållande40.9%

Hur har PDEX utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/26 06:19
Aktiekurs vid dagens slut2026/05/22 00:00
Intäkter2026/03/31
Årlig intjäning2025/06/30

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Pro-Dex, Inc. bevakas av 1 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Edward WooAscendiant Capital Markets LLC